TEV-56286: administered orally
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.
The planned total duration of the trial is approximately 100 weeks.
| Facility | City | Region | Status |
|---|---|---|---|
| Teva Investigational Site 15554 | La Jolla | California | Recruiting |
| Teva Investigational Site 15544 | Boca Raton | Florida | Recruiting |
| Teva Investigational Site 15555 | Tampa | Florida | Recruiting |
| Teva Investigational Site 15546 | Kansas City | Kansas | Recruiting |
| Teva Investigational Site 15549 | New York | New York | Recruiting |
| Teva Investigational Site 15551 | New York | New York | Recruiting |
| Teva Investigational Site 15548 | Pittsburgh | Pennsylvania | Recruiting |
| Teva Investigational Site 15543 | Spokane | Washington | Recruiting |
| Teva Investigational Site 35290 | Bordeaux | France | Recruiting |
| Teva Investigational Site 35289 | Marseille | France | Not Yet Recruiting |
| Teva Investigational Site 35291 | Paris | France | Recruiting |
| Teva Investigational Site 35292 | Toulouse | France | Recruiting |
| Teva Investigational Site 32818 | Dresden | Germany | Recruiting |
| Teva Investigational Site 32822 | Düsseldorf | Germany | Recruiting |
| Teva Investigational Site 32825 | Kassel | Germany | Recruiting |
| Teva Investigational Site 32824 | Marburg | Germany | Recruiting |
| Teva Investigational Site 32820 | München | Germany | Recruiting |
| Teva Investigational Site 32819 | Münster | Germany | Recruiting |
| Teva Investigational Site 80203 | Haifa | Israel | Recruiting |
| Teva Investigational Site 80204 | Tel Aviv | Israel | Recruiting |
| Teva Investigational Site 30299 | Bologna | Italy | Recruiting |
| Teva Investigational Site 30297 | Catania | Italy | Recruiting |
| Teva Investigational Site 30298 | Milan | Italy | Recruiting |
| Teva Investigational Site 30296 | Roma | Italy | Recruiting |
| Teva Investigational Site 30295 | Salerno | Italy | Recruiting |
| Teva Investigational Site 84139 | Fuchū | Japan | Recruiting |
| Teva Investigational Site 84137 | Niigata | Japan | Recruiting |
| Teva Investigational Site 84138 | Sagamihara | Japan | Recruiting |
| Teva Investigational Site 84141 | Sanda-shi | Japan | Recruiting |
| Teva Investigational Site 84135 | Sendai | Japan | Recruiting |
| Teva Investigational Site 31324 | Barcelona | Spain | Recruiting |
| Teva Investigational Site 31323 | Barcelona | Spain | Recruiting |
| Teva Investigational Site 31321 | Barcelona | Spain | Recruiting |
| Teva Investigational Site 31320 | Pamplona | Spain | Recruiting |
| Teva Investigational Site 31322 | Seville | Spain | Recruiting |
| Teva Investigational Site 31319 | Valencia | Spain | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07197866 on ClinicalTrials.gov ↗ ← All trials in the USA